Viking Therapeutics, Inc. (1VT.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 06:56PM CEST
| Previous close | 63.14 |
| Open | 64.00 |
| Bid | 61.26 x 290000 |
| Ask | 61.74 x 280000 |
| Day's range | 63.00 - 66.76 |
| 52-week range | 8.62 - 91.50 |
| Volume | |
| Avg. volume | 2,266 |
| Market cap | 6.949B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
- Zacks
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
- Simply Wall St.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 72% of the company
Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to their...
© 2024 Yahoo. All rights reserved.